Pfizer Reports Interim Results of Paxlovid (COVID-19 Oral Antiviral Therapy) in P-II/III EPIC-HR Study for the Treatment of COVID-19
Shots: The P-II/III EPIC-HR evaluates Paxlovid vs PBO in non-hospitalized adult patients with COVID-19 who are at high risk of progressing to severe illness In an interim analysis, the therapy showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause in patients treated within 3 days of symptom onset. In the […]